February 12, 2021

EuropaBio Response to Public Consultation on the Evaluation of Patient Rights in Cross-Border Healthcare

EuropaBio sees the Directive on cross-border healthcare as an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases.
January 20, 2021

Revision of the EU legislation on medicines for children and rare diseases

Read our submission to the European Commission’s Inception Impact Assessment titled “Revision of the EU legislation on medicines for children and rare diseases“.
December 24, 2020

Joint Statement: Comitology Reform Threatens Innovation

November 30, 2020

Call for more effective EU regulation of Clinical Trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms

Call for more effective EU regulation of clinical trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms
October 20, 2020

EuropaBio on Use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making

EuropaBio Position Paper on the use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making.
October 19, 2020

Application of the ATMP Hospital Exemption in the EU

EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
September 30, 2020

EuropaBio Patient engagement with the European Medicines Agency

EuropaBio Patient engagement with the European Medicines Agency
August 13, 2020

Statement in response to the publication of the European Commission’s evaluation of the Orphan and Paediatric Regulations

Read our Statement in response to the publication of the European Commission’s evaluation of the Orphan and Paediatric Regulations.
August 3, 2020

Joint Statement on the Health Innovation Partnership Proposal

Health industry sectors, representing pharmaceutical and medical technology companies welcome the publication of the Partnership Proposal as a significant milestone towards a European Partnership for Health Innovation.
July 30, 2020

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation

Joint response of EuropaBio and BIO on the EU Data Strategy Consultation.
July 30, 2020

EuropaBio response to the public consultation on the Roadmap for an EU Pharmaceutical Strategy

EuropaBio response to the public consultation on the Roadmap for an EU Pharmaceutical Strategy.
July 30, 2020

EuropaBio response to the Work Programme of the eHealth Stakeholder Group

Read our response on the eHSG Work Programme 2020-2022.
July 15, 2020

EuropaBio position paper on the Farm to Fork Strategy

Read our position paper on the Farm to Fork strategy.
June 30, 2020

EuropaBio observations in response to Europe’s Beating Cancer Plan

EuropaBio welcomes the European Commission’s commitment to develop a European plan to fight cancer and is supportive of its overarching approach in tackling all key stages of the disease: prevention, early diagnosis, treatment, and quality of life. Above all, we strongly advocate the employment of supportive measures for health innovation to ensure that novel cancer treatments move from the laboratory to the hospital bedside as swiftly as possible.
June 22, 2020

EuropaBio position on the EU Biodiversity Strategy for 2030

Read our position on the EU 2030 Biodiversity Strategy.
Become a member